hackint0sh/New-Dataset huggingface dataset:
To test the effects of BMS on PA, participants will be randomly assigned to an exercise intervention that either includes BMS or does not include BMS. Participants will attend a supervised group strength training (ST) (30 min/day) and aerobic exercise (AE) (30-50 min/day) session for 3 days/week for the first 2 months, 1 day/week for the next 2 months (while encouraging participants to independently perform both AE and ST on other days), and independently for the final 2 months (always with a goal of performing \>150min/week AE and 3 days/week of ST for 30 min/day. conditions: Cognitively Normal Older Adults studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: Music name: Exercise measure: Physical activity (objective) measure: Ecological Momentary Assessment (EMA): Affective response to PA measure: Ecological Momentary Assessment (EMA): Perceived autonomy measure: Ecological Momentary Assessment (EMA): Perceived exertion measure: Ecological Momentary Assessment (EMA): Behavioral intention measure: Ecological Momentary Assessment (EMA): Physical Activity setting measure: Ecological Momentary Assessment (EMA): Anticipated, remembered, and incidental affect measure: Ecological Momentary Assessment (EMA): Social Support for Exercise measure: Physical activity (self-report) measure: Cognitive performance - General measure: Cognitive performance - Tower of London measure: Cognitive performance - NIH Toolbox Oral Reading Recognition Test measure: Cognitive performance - NIH Toolbox List Sort Working Memory Test measure: Cognitive performance - NIH Toolbox Picture Sequence Test measure: Cognitive performance - NIH Toolbox Dimensional Change Card Sort Test measure: Cognitive performance - NIH Toolbox Flanker Inhibitory Control and Attention Test measure: Cognitive performance - Mnemonic Similarity Task measure: Cognitive performance - Perceptual Discrimination Task measure: Health Related Quality of Life measure: Physical activity (subjective) measure: Music Reward Experience measure: Treatment Satisfaction measure: Body Mass Index measure: Waist/Hip/Leg Circumference measure: Sagittal Diameter measure: Blood Pressure measure: Handgrip Strength measure: Timed Up and Go (TUG) measure: 10-Meter Walk measure: 4-Stage Balance Test measure: 6-Minute Walk Test (6MWT) measure: 30-second Chair Stand sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: University of North Carolina at Greensboro status: RECRUITING city: Greensboro state: North Carolina zip: 27402-6170 country: United States name: Project Coordinator, MS role: CONTACT phone: 336-334-4765 email: istep@uncg.edu name: Jennifer L Etnier, PhD role: PRINCIPAL_INVESTIGATOR name: Shin Park, PhD role: PRINCIPAL_INVESTIGATOR lat: 36.07264 lon: -79.79198 hasResults: False
nctId: NCT06364176 id: STUDY00149479 briefTitle: Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis. overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-05 date: 2027-10 date: 2024-04-15 date: 2024-04-22 name: University of Kansas Medical Center class: OTHER briefSummary: The goal of this clinical trial is to test use of losartan in those with cystic fibrosis (CF) on modulator therapy. The main question it aims to answer is if treatment with losartan improves response of the CF transmembrane conductance regulator (CFTR) channel to modulator therapy.
Participants will be asked take losartan or placebo for twelve weeks and will have changes in sweat chloride levels measured as a marker of CFTR function. conditions: Cystic Fibrosis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 42 type: ESTIMATED name: Losartan name: Placebo measure: Sweat chloride measure: Lung function - absolute measure: Lung function - relative measure: Transforming growth factor (TGF)-beta1 - airway measure: TGF-beta1 - systemic measure: Inflammatory mediators - airway measure: Inflammatory mediators - systemic measure: CFQ-R measure: Adverse events sex: ALL minimumAge: 12 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University of Kansas Medical Center city: Kansas City state: Kansas zip: 66160 country: United States name: Charles Bengtson, MD, MSc role: CONTACT phone: 913-588-6000 name: Carolina Aguiar role: CONTACT phone: 9139459295 name: Matthias Salathe, M.D. role: SUB_INVESTIGATOR name: Andreas Schmid, M.D. role: SUB_INVESTIGATOR lat: 39.11417 lon: -94.62746 hasResults: False
nctId: NCT06364163 id: 697716 briefTitle: Effect of Herring Oil Concentrate on LDL Cholesterol Concentration in Adults overallStatus: NOT_YET_RECRUITING date: 2024-08-12 date: 2026-12-31 date: 2027-12-31 date: 2024-04-15 date: 2024-04-15 name: University of Bergen class: OTHER name: The Norwegian Seafood Research Fund briefSummary: High cholesterol concentration is a major risk factor for cardiovascular disease (CVD), and consumption of fish has been associated with a lower CVD risk in several studies. The beneficial health effects of consuming fish have traditionally been ascribed to the long-chain PUFA (LC-PUFA) EPA (C20:5n-3) and DHA (C22:6n-3), although consumption of fish oils or concentrates with high EPA and DHA contents does not affect the cholesterol concentration in humans and lowers the cholesterol concentration in rats and mice only when given in very high doses. Fish oils contain a plethora of fatty acids besides EPA and DHA, and in recent years, increased focus has been on the long-chain MUFA (LC-MUFA) cetoleic acid (C22:1n-11). Cetoleic acid is found in high amounts in oils from certain fish species such as herring, which has relatively low contents of both EPA and DHA. The investigators have recently summarised and meta-analysed the available literature that investigates the effects of diets containing fish oils or fish oil concentrates that have a high content of cetoleic acid but low or no content of EPA and DHA on cholesterol concentration in rodents, showing that cetoleic acid-rich fish oils and concentrates prevent high cholesterol concentration. conditions: High Cholesterol studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Herring oil concentrate name: Control measure: Serum concentration of LDL-cholesterol measure: Serum concentration of HDL-cholesterol measure: Serum concentration of total cholesterol measure: Serum concentrations of apolipoproteins measure: Serum concentrations of amino acids metabolites measure: Serum concentration of one-carbon pathway metabolites measure: Fatty acid composition in leukocytes measure: Serum concentration of glucose measure: Serum concentration of insulin measure: Urine concentrations of cystatin C measure: Urine concentrations of T cell immunoglobulin mucin-1 (TIM-1) measure: Body composition sex: ALL minimumAge: 20 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Bergen city: Bergen country: Norway name: Oddrun A Gudbrandsen, PhD role: CONTACT phone: 55975553 phoneExt: 47 email: nkjgu@uib.no lat: 60.39299 lon: 5.32415 hasResults: False
nctId: NCT06364150 id: MAGIC6 briefTitle: Therapeutic Use of Angiopoietin-Primed Autologous Peripheral Blood Stem Cell in Myocardial Infarction acronym: MAGICcell6 overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2026-08-01 date: 2024-04-15 date: 2024-04-15 name: Seoul National Hospital class: OTHER_GOV briefSummary: This study will evaluate the efficacy and safety of "Therapeutic Use of Autologous-Primed Autologous Peripheral Blood Stem Cell Treatment for Myocardial Regeneration in Acute Myocardial Infarction". conditions: Acute Myocardial Infarction studyType: INTERVENTIONAL phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is a single arm, open label interventional study primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Autologous Peripheral Blood Stem Cell injection measure: Left ventricular systolic function measure: Regional wall motion score index measure: B-natriuretic peptide level measure: 6-minute walk test measure: All-cause death measure: Target lesion Revascularization measure: Readmssion measure: Cardiovascular death measure: non-Target lesion Revascularization sex: ALL minimumAge: 19 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06364137 id: 73203 briefTitle: Engagement and Clinical Impact of the Teleo Virtual Therapy Platform in Clinical Settings - Pilot RCT overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2025-06-30 date: 2025-06-30 date: 2024-04-15 date: 2024-04-15 name: Stanford University class: OTHER name: National Institute of Mental Health (NIMH) name: MainSquare Co. (dba 'Teleo') briefSummary: The research study will examine engagement in telehealth for children undergoing psychotherapy. The study in Phase I entails a pilot randomized trial with a goal to enroll 42 families, examining patient engagement in Teleo, a virtual therapy platform specifically designed for psychotherapy with youth, as compared to standard video conferencing.
Engagement will be assessed using well-established measures - PRIME-O (modified) video coding, MTT-Y/MTTCG and attendance data (sessions 1-4). Clinicians in the study will deliver therapy to clients for 4 sessions, providing opportunity to measure temporal sustainment of any engagement differences. conditions: Anxiety Disorders conditions: Mood Disorders studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 42 type: ESTIMATED name: Teleo name: Standard videoconferencing measure: PRIME-O Video Coding Score measure: My Thoughts about Therapy - Caregiver (MTT-CG) engagement questionnaire scores measure: My Thoughts about Therapy - Youth (MTT-Y) engagement questionnaire scores measure: Attendance during Psychotherapy Sessions sex: ALL minimumAge: 5 Years maximumAge: 14 Years stdAges: CHILD facility: Stanford University city: Stanford state: California zip: 94305 country: United States lat: 37.42411 lon: -122.16608 hasResults: False
nctId: NCT06364124 id: Beijing_LH_CCU2024 briefTitle: Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction overallStatus: RECRUITING date: 2023-06-01 date: 2024-06-01 date: 2025-06-01 date: 2024-04-15 date: 2024-04-18 name: Beijing Luhe Hospital class: OTHER briefSummary: Acute ST-segment elevation myocardial infarction (STEMI) is a common manifestation of cardiovascular emergencies. Percutaneous coronary intervention (PCI) and guideline-recommended pharmacotherapy have reduced mortality rates associated with STEMI, but the incidence of recurrent ischemic events, particularly early ischemic events, remains high. Current research suggests that low-density lipoprotein cholesterol (LDL-C) levels not meeting guideline-recommended levels and inflammation are closely related to early recurrent ischemic events. Evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, rapidly and effectively reduces LDL-C levels and suppresses inflammation. Long-term use in patients with acute coronary syndromes can reverse atherosclerosis and improve prognosis. However, data on its use in STEMI patients are limited, particularly regarding the cardioprotective effects of preoperative administration of 420mg evolocumab subcutaneous injection. This study aims to evaluate the effects of administering evolocumab 420mg before emergency PCI on lipid profiles, inflammatory markers, myocardial injury, and short-term prognosis in STEMI patients through a single-center, randomized, open-label study. It aims to provide theoretical evidence for further reducing the risk of recurrent cardiovascular events in STEMI and identifying more optimized treatment strategies. conditions: STEMI studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 84 type: ESTIMATED name: evolocumab name: Atorvastatin measure: Average percent change from baseline in LDL-C levels to discharge and day 30 measure: Average percent change from baseline in total cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A and apolipoprotein B to discharge and day 30 measure: Average percent change from baseline in MMP-9, CSF-1, IL-18R1 to discharge and day 30 measure: Number of cardiovascular events to day 30 sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing luhe hospital status: RECRUITING city: Beijing country: China name: rui yan role: CONTACT phone: 17746570262 email: yanrui4112@163.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06364111 id: Vibrabot Capsule briefTitle: Comparative Study on the Efficacy of Vibrabot Capsule and Polyethylene Glycol for Chronic Functional Constipation overallStatus: RECRUITING date: 2024-01-08 date: 2025-06-14 date: 2025-08-30 date: 2024-04-15 date: 2024-04-15 name: Beijing Tsinghua Chang Gung Hospital class: OTHER briefSummary: This is a single-center trial that enrolls 20 18 to 85-year-old patients with moderate to severe FC to study the efficacy of Vibrabot capsule (dosage: 5 capsules/week) and polyethylene glycol, as well as the mechanism of action of the Vibrabot capsule. conditions: Chronic Functional Constipation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 45 type: ESTIMATED name: Vibrabot capsule name: polyethylene glycol measure: The proportions of responders to the three therapies during the treatment period. measure: Evaluation of intestinal motility measure: Assessment of neurotransmitters in peripheral blood measure: Assessment of changes in intestinal flora measure: Evaluation of the treatment cycle of Vibrabot Capsules sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: XuanJiang status: RECRUITING city: Beijing state: Beijing zip: 102218 country: China name: Xuan Jiang, professor role: CONTACT phone: 13671006525 email: jxa01998@btch.edu.cn name: Jinzhe Liu, physician role: CONTACT phone: 18810831618 email: ljza02528@btch.edu.cn lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06364098 id: prevention of PPH briefTitle: Comparative Study Between the Roles of Intrauterine Misoprostol Versus the Sublingual Route for Prevention of Postpartum Blood Loss in Elective Cesarean Sections overallStatus: COMPLETED date: 2022-01-01 date: 2023-02-01 date: 2023-02-01 date: 2024-04-15 date: 2024-04-15 name: Cairo University class: OTHER briefSummary: Study design:
192 pregnant women at the age range from 20 to 35 years, with BMI \< 30kg/m2 presenting with a full-term singleton healthy living fetus (gestational age \>39 weeks confirmed by the first day of the last menstrual period or first-trimester ultrasound scan) and candidate for elective cesarean delivery (Previous one or two cesarean section) were included in our study. Patients with uterine over distension as due to multiple pregnancies or polyhydramnios, multipara (parity ≥3), women with uterine fibroids, antepartum hemorrhage presentation such as placenta previa, placental abruption or vasa previa, moderate to severe anemia with hemoglobin level \<9mg/dl, patient on anticoagulant during pregnancy or having coagulopathy or thrombocytopenia or blood dyscrasias, hypertension, cardiovascular, DM, hepatic, or renal disorders and women with any contraindication for the use of misoprostol or oxytocin as allergy to prostaglandin and concomitant drugs that have drug interaction with prostaglandins as topical dinoprostone, antacids containing magnesium were excluded from our study. conditions: Postpartum Hemorrhage studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: PARTICIPANT count: 192 type: ACTUAL name: Misoprostol measure: The amount of blood loss measure: Changes in hematocrit values in both groups after delivery measure: Changes in Hemoglobin level measured by gm/dl in both groups after delivery measure: Incidence of side effects of study medications sex: FEMALE minimumAge: 20 Years maximumAge: 35 Years stdAges: ADULT facility: Faculty of medicine, Kasr Alainy city: Cairo state: Al Manyal zip: 11956 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06364085 id: DBS2024 briefTitle: Enhancing Epilepsy Management With Precision Deep Brain Stimulation acronym: EPI-BOOST overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-01 date: 2026-06 date: 2024-04-15 date: 2024-04-15 name: Nova Scotia Health Authority class: OTHER briefSummary: The goal of this study is to evaluate the effectiveness of objective neural response feedback on deep brain stimulation (DBS) programming for drug-resistant epilepsy in a prospective observational cohort study. conditions: Epilepsy, Drug Resistant studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Neuromodulation programming measure: Seizure reduction measure: Change in disease score on Patient Weighted Quality Of Life In Epilepsy measure: Change in depression score on Neurological Disorders Depression Inventory in Epilepsy measure: Change in anxiety score on Anxiety General Anxiety Disorder-7 sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Queen Elizabeth Health Science Centre city: Halifax state: Nova Scotia zip: B3H 3A7 country: Canada name: Lutz Weise role: CONTACT lat: 44.64533 lon: -63.57239 hasResults: False
nctId: NCT06364072 id: PDC 01-0202 id: 2023-504023-63-00 type: CTIS briefTitle: Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2024-09-15 date: 2024-09-20 date: 2024-04-15 date: 2024-04-15 name: Cessatech A/S class: INDUSTRY briefSummary: The proposed study aims to investigate the safety, tolerability, analgesic efficacy, and feasibility of intranasal sufentanil/ketamine (CT001) in pediatric participants attending an acute care (i.e. emergency) setting. The study is a part of the clinical development plan for the development of CT001 nasal spray for treatment of acute pain in children. conditions: Pain studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 150 type: ESTIMATED name: CT001 measure: To assess the safety and tolerability measure: To evaluate the analgesic effect measure: To assess medication errors sex: ALL minimumAge: 1 Year maximumAge: 17 Years stdAges: CHILD hasResults: False
nctId: NCT06364059 id: aSDH-TT briefTitle: A Comparative Analysis of Prognostic Factors for Functional Outcomes in Patients With Acute Subdural Hematoma overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-09 date: 2024-11 date: 2024-04-15 date: 2024-04-15 name: Charles University, Czech Republic class: OTHER name: Military University Hospital, Prague briefSummary: Acute subdural hematoma (ASDH) is the most common intracranial traumatic lesion that requires surgical intervention. Although there is extensive published research on acute subdural, there remains uncertainty regarding mortality risk and functional outcomes for patients. This study aims to evaluate the effectiveness of contemporary scoring systems in different age groups of ASDH patients to predict functional outcomes. conditions: Acute Subdural Hematoma conditions: Acquired Brain Injury studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 200 type: ESTIMATED name: Decompressive craniectomy with evacuation of subdural hematoma measure: Level of consciousness at time of injury measure: Initial size of subdural hematoma measure: Initial midline shift measure: Chronic use of anti-clotting medication measure: Trauma severity analyzed using Injury Severity Score (ISS). measure: Severity of illness analyzed using Acute Physiology and Chronic Health Evaluation II score (APACHE II) measure: The Glasgow Outcome Scale (GOS) at the time of discharge from the Intensive Care (IC). measure: The Glasgow Outcome Scale Extended (GOSE) evaluation of global disability and recovery after 6 months. measure: The Glasgow Outcome Scale Extended (GOSE) evaluation of global disability and recovery after 12 months. measure: Number of revisions. measure: Time from injury to surgery. measure: Time of operation. measure: The need for reversal of the effects of anticoagulants. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Military University Hospital Prague city: Praha zip: 16209 country: Czechia name: Michal Soták, M.D., Ph.D. role: CONTACT phone: +420973202999 email: michal.sotak@uvn.cz name: Tomáš Tyll, M.D., Ph.D. role: CONTACT phone: +420973202999 email: tomas.tyll@uvn.cz name: Tomáš Tyll, M.D., Ph.D. role: PRINCIPAL_INVESTIGATOR lat: 50.08804 lon: 14.42076 hasResults: False
nctId: NCT06364046 id: ZJLS-KLDMIR-22006 briefTitle: Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-12-31 date: 2025-12-31 date: 2024-04-15 date: 2024-04-15 name: The Central Hospital of Lishui City class: OTHER briefSummary: This project aims to conduct a prospective, single-center, randomized, open-label, two-arm study to compare the clinical efficacy and safety of bronchial arterial chemoembolization with drug-eluting beads (DEB-BACE) combined with serplulimab versus conventional intravenous chemotherapy combined with Serplulimab as first-line treatment for SCLC patients. The objective is to provide evidence-based support for clinical practice. conditions: Carcinoma conditions: Small Cell Lung Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 56 type: ESTIMATED name: Drug-eluting beads bronchial arterial chemoembolization name: Serplulimab name: Intravenous chemotherapy measure: Objective response rate measure: Progression Free Survival measure: Overall Survival measure: Time to tumor untreatable progression measure: Disease Control Rate measure: Duration of Overall Response measure: Tumor biomarkers measure: Tumor biomarkers measure: Tumor biomarkers measure: Tumor biomarkers measure: Eastern Cooperative Oncology Group Score measure: Recurrence rate of hemoptysis measure: Quality of life Questionare-Core score measure: The incidence of adverse events and serious adverse events measure: Pain assessment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Lishui central hospital city: Lishui state: Zhejiang zip: 323000 country: China lat: 28.46042 lon: 119.91029 hasResults: False